drugset / Trial / NCT00920933

Effect of AIN457 on Ozone-induced Airway Neutrophilia Compared to Placebo and Corticosteroid in Healthy Subjects

NCT00920933

Phase 1/2 Completed 24 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindBasic science

Summary

This study will assess the ability of AIN457 to attenuate the increase in airway neutrophils that is seen following ozone exposure. Healthy subjects will be treated with AIN457, placebo, or oral corticosteroid and the response to a subsequent ozone exposure will be evaluated.

Timeline

Start
2009-01
Primary completion
2009-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Prednisolone Other / unclassified Oral
Subject Secukinumab Monoclonal antibody Intravenous

Indications

No indication recorded.